Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model

por Krishnatry, Anu Shilpa, Voelkner, Alexander, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine
Publicado 2021

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors

por Krishnatry, Anu Shilpa, Hanze, Eva, Bergsma, Tim, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine
Publicado 2021

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

por Dawson, Mark A., Borthakur, Gautam, Huntly, Brian J.P., Karadimitris, Anastasios, Alegre, Adrian, Chaidos, Aristeidis, Vogl, Dan T., Pollyea, Daniel A., Davies, Faith E., Morgan, Gareth J., Glass, Jacob L., Kamdar, Manali, Mateos, Maria-Victoria, Tovar, Natalia, Yeh, Paul, Delgado, Regina García, Basheer, Faisal, Marando, Ludovica, Gallipoli, Paolo, Wyce, Anastasia, Krishnatry, Anu Shilpa, Barbash, Olena, Bakirtzi, Evi, Ferron-Brady, Geraldine, Karpinich, Natalie O., McCabe, Michael T., Foley, Shawn W., Horner, Thierry, Dhar, Arindam, Kremer, Brandon E., Dickinson, Michael
Publicado 2023